"10.1371_journal.pone.0083832","plos one","2013-12-31T00:00:00Z","Cecilia Garofalo; Mariantonietta Capristo; Maria Cristina Manara; Caterina Mancarella; Lorena Landuzzi; Antonino Belfiore; Pier-Luigi Lollini; Piero Picci; Katia Scotlandi","CRS Development of Biomolecular Therapies, Experimental Oncology Laboratory, Rizzoli Orthopedic Institute, Bologna, Italy; Experimental Oncology Laboratory, Rizzoli Orthopedic Institute, Bologna, Italy; Department of Health, University of Catanzaro, Catanzaro, Italy; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy","Conceived and designed the experiments: CG KS. Performed the experiments: CG MC MCM CM LL. Analyzed the data: CG MC MCM CM LL AB KS. Contributed reagents/materials/analysis tools: KS PP PLL AB. Wrote the paper: CG KS.","The anti-IGF-IR drugs used in this study were kindly provided by: Immunogen (AVE1642 HAb; Waltham, AM), Pfizer (CP-751,871/Figitumumab; San Diego, California), and Novartis (NVP-AEW541 and NVP-BEZ235; Basel, Switzerland). An ifosfamide analog not requiring metabolic activation used in this study was kindly provided by Baxter Oncology GmbH (Frankfurt, Germany), and Actinomycin-D was provided by Ovation Healthcare International (Dublin, Ireland). There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2013","12","Cecilia Garofalo","CG",9,TRUE,2,5,7,2,TRUE,TRUE,FALSE,0,NA,FALSE
